Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
69 hedge funds and large institutions have $166M invested in Adaptimmune Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 13 closing their positions.
1,925% more call options, than puts
Call options by funds: $81K | Put options by funds: $4K
36% more capital invested
Capital invested by funds: $122M → $166M (+$43.9M)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more funds holding
Funds holding: 68 → 69 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.51% less ownership
Funds ownership: 12.1% → 11.59% (-0.51%)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$6M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.06M |
| 3 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$800K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$670K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$517K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.25M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.1M |
| 3 |
BlackRock
New York
|
-$715K |
| 4 |
Goldman Sachs
New York
|
-$493K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$398K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RA
76
RFG Advisory
Birmingham,
Alabama
| – | -$21K | -10,000 | Closed |
|
|
RPCA
77
Running Point Capital Advisors
El Segundo,
California
| – | -$11K | -10,000 | Closed |
|
|
LC
78
Lindbrook Capital
Calabasas,
California
| – | -$3K | -3,084 | Closed |
|
|
ACM
79
Aquatic Capital Management
Chicago,
Illinois
| – | -$1K | -1,100 | Closed |
|
|
QCG
80
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -1,046 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$94 | -58 | -67% |
|
ADAP Hedge Fund Activity: Q4 2022 in Review
69 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2022, worth a combined $166M — up 36% from $122M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ADAP positions and 13 closed out — a net gain of 2 holders — while 16 added to existing stakes and 23 trimmed.
The largest buyer was Bank of America, adding an estimated $6M. The largest seller was PFM Health Sciences, cutting an estimated $7.25M.
- 69 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2022, up from 68 in Q3 2022.
- Funds reported $166M of Adaptimmune Therapeutics stock for Q4 2022, up 36% quarter-over-quarter.
- 15 funds opened new Adaptimmune Therapeutics positions in Q4 2022 and 13 closed out, a net change of +2 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2022 was Bank of America, an estimated $6M added.
- The largest Adaptimmune Therapeutics seller in Q4 2022 was PFM Health Sciences, an estimated $7.25M sold.
Based on aggregated 13F filings for Q4 2022.